These cells can recognize tumor antigens and then target tumor cells after activation, and decreased infiltration or dysfunction of CD8+ T cells in the tumor microenvironment (TME) results in poor clinical outcomes in patients receiving many cancer therapies (24). Here, CD8A is linked to neoplasm.